TRPV1 and rheumatoid arthritis: Knockdown of TRPV1 in human primary CD4+ T cells reduces the expression of CD25 and shared epitope-positive HLA-DR alleles and diminishes the generation of anti-citrullinated protein antibodies (ACPA) in RA patients (42).In addition, TRPV1 antagonists can reduce the production of inflammatory factors.